371 related articles for article (PubMed ID: 26617778)
61. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
Erben P; Ströbel P; Horisberger K; Popa J; Bohn B; Hanfstein B; Kähler G; Kienle P; Post S; Wenz F; Hochhaus A; Hofheinz RD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1032-8. PubMed ID: 20947270
[TBL] [Abstract][Full Text] [Related]
62. Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial.
Feng YR; Zhu Y; Liu LY; Wang WH; Wang SL; Song YW; Wang X; Tang Y; Liu YP; Ren H; Fang H; Zhang SP; Liu XF; Yu ZH; Li YX; Jin J
Oncotarget; 2016 May; 7(18):25576-84. PubMed ID: 27014909
[TBL] [Abstract][Full Text] [Related]
63. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial.
Fokas E; Fietkau R; Hartmann A; Hohenberger W; Grützmann R; Ghadimi M; Liersch T; Ströbel P; Grabenbauer GG; Graeven U; Hofheinz RD; Köhne CH; Wittekind C; Sauer R; Kaufmann M; Hothorn T; Rödel C;
Ann Oncol; 2018 Jul; 29(7):1521-1527. PubMed ID: 29718095
[TBL] [Abstract][Full Text] [Related]
64. Response to preoperative chemoradiation in stage II and III rectal cancer.
Brown CL; Ternent CA; Thorson AG; Christensen MA; Blatchford GJ; Shashidharan M; Haynatzki GR
Dis Colon Rectum; 2003 Sep; 46(9):1189-93. PubMed ID: 12972962
[TBL] [Abstract][Full Text] [Related]
65. Clinical Impact of Preoperative Albumin-Globulin Ratio in Patients with Rectal Cancer Treated with Preoperative Chemoradiotherapy.
Toiyama Y; Oki S; Okugawa Y; Ide S; Yasuda H; Fujikawa H; Yoshiyama S; Hiro J; Ohi M; Inoue Y; Araki T; Kusunoki M
Oncology; 2018; 95(5):270-280. PubMed ID: 29996133
[TBL] [Abstract][Full Text] [Related]
66. Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy.
Hall MD; Schultheiss TE; Smith DD; Fakih MG; Wong JY; Chen YJ
Acta Oncol; 2016 Dec; 55(12):1392-1399. PubMed ID: 27762654
[TBL] [Abstract][Full Text] [Related]
67. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
[TBL] [Abstract][Full Text] [Related]
68. Association between neoadjuvant chemoradiation and survival for patients with locally advanced rectal cancer.
Sun Z; Adam MA; Kim J; Turner MC; Fisher DA; Choudhury KR; Czito BG; Migaly J; Mantyh CR
Colorectal Dis; 2017 Dec; 19(12):1058-1066. PubMed ID: 28586509
[TBL] [Abstract][Full Text] [Related]
69. A randomized controlled pilot study to compare capecitabine-oxaliplatin with 5-FU-leucovorin as neoadjuvant concurrent chemoradiation in locally advanced adenocarcinoma of rectum.
Saha A; Ghosh SK; Roy C; Saha ML; Choudhury KB; Chatterjee K
J Cancer Res Ther; 2015; 11(1):88-93. PubMed ID: 25879343
[TBL] [Abstract][Full Text] [Related]
70. Chemoradiation in rectal squamous cell carcinoma: Bi-institutional case series.
Loganadane G; Servagi-Vernat S; Schernberg A; Schlienger M; Touboul E; Bosset JF; Huguet F
Eur J Cancer; 2016 May; 58():83-9. PubMed ID: 26974707
[TBL] [Abstract][Full Text] [Related]
71. The local immune phenotype influences prognosis in patients with nodal-positive rectal cancer after neoadjuvant chemoradiation.
Schollbach J; Kircher S; Wiegering A; Anger F; Rosenwald A; Germer CT; Löb S
Int J Colorectal Dis; 2020 Feb; 35(2):365-370. PubMed ID: 31828368
[TBL] [Abstract][Full Text] [Related]
72. Tumor regression grades: potential outcome predictor of locally advanced rectal adenocarcinoma after preoperative radiotherapy.
Peng YF; Yu WD; Pan HD; Wang L; Li M; Yao YF; Zhao J; Gu J
World J Gastroenterol; 2015 Feb; 21(6):1851-6. PubMed ID: 25684951
[TBL] [Abstract][Full Text] [Related]
73. Transanal local excision for distal rectal cancer and incomplete response to neoadjuvant chemoradiation - does baseline staging matter?
Perez RO; Habr-Gama A; São Julião GP; Proscurshim I; Coelho AQ; Figueiredo MN; Fernandez LM; Gama-Rodrigues J
Dis Colon Rectum; 2014 Nov; 57(11):1253-9. PubMed ID: 25285691
[TBL] [Abstract][Full Text] [Related]
74. Impact of perineural and lymphovascular invasion on oncological outcomes in rectal cancer treated with neoadjuvant chemoradiotherapy and surgery.
Cienfuegos JA; Rotellar F; Baixauli J; Beorlegui C; Sola JJ; Arbea L; Pastor C; Arredondo J; Hernández-Lizoáin JL
Ann Surg Oncol; 2015 Mar; 22(3):916-23. PubMed ID: 25190129
[TBL] [Abstract][Full Text] [Related]
75. Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma.
Fakih MG; Bullarddunn K; Yang GY; Pendyala L; Toth K; Andrews C; Rustum YM; Ross ME; Levea C; Puthillath A; Park YM; Rajput A
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):650-7. PubMed ID: 18565686
[TBL] [Abstract][Full Text] [Related]
76. Role of neoadjuvant treatment in cT3N0M0 rectal cancer.
Pasetto LM; Friso ML; Pucciarelli S; Basso U; Rugge M; Sinigaglia G; Rossi E; Compostella A; Toppan P; Agostini M; Monfardini S
Anticancer Res; 2008; 28(6B):4129-35. PubMed ID: 19192672
[TBL] [Abstract][Full Text] [Related]
77. T3+ and T4 rectal cancer patients seem to benefit from the addition of oxaliplatin to the neoadjuvant chemoradiation regimen.
Martijnse IS; Dudink RL; Kusters M; Vermeer TA; West NP; Nieuwenhuijzen GA; van Lijnschoten I; Martijn H; Creemers GJ; Lemmens VE; van de Velde CJ; Sebag-Montefiore D; Glynne-Jones R; Quirke P; Rutten HJ
Ann Surg Oncol; 2012 Feb; 19(2):392-401. PubMed ID: 21792506
[TBL] [Abstract][Full Text] [Related]
78. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
[TBL] [Abstract][Full Text] [Related]
79. The role of COX-2 and Ki-67 over-expression in the prediction of pathologic response of rectal cancer to neoadjuvant chemoradiation therapy.
Jafarian AH; Kermani AT; Esmaeili J; Roshan NM; Seilanian-Toosi M; Omidi AA; Shahri MK
Indian J Cancer; 2016; 53(4):548-551. PubMed ID: 28485348
[TBL] [Abstract][Full Text] [Related]
80. Prognostic Implications of Pathological Response to Neoadjuvant Chemoradiation in Pathologic Stage III Rectal Cancer.
Karagkounis G; Thai L; Mace AG; Wiland H; Pai RK; Steele SR; Church JM; Kalady MF
Ann Surg; 2019 Jun; 269(6):1117-1123. PubMed ID: 31082910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
